DASL-HiCaP #ESMO26
Very high-risk prostate ca Ph3 n=1,106
RT+ADT+Darolutamide vs placebo
MFS-CI: 5% vs 11% events | 4y 95% vs 88%
HR 0.42 (0.27-0.66) p=0.0001
Another positive study in high-risk prostate cancer, increasing the treatment options for our patients.
- @GhosnMd
@myESMO @GustaveRoussy @GRAlumni #ProstateCancer
102 views · 3 likes · 1 repost · 0 replies
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgPerioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgTarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgDarolutamide with androgen deprivation therapy (ADT) and definitive or salvage locoregional radiation therapy (RT) for localised, very high-risk prostate cancer: Interim analysis of an international, placebo-controlled, randomised phase 3 t
https://esmocongress.esmo.orgSource: OncLive.com · x.com